A phase 2 trial of PRL3-ZUMAB in advanced solid tumours, run by Intra-IMMUSG Pte Ltd, active and no longer recruiting.
PRL3-Zumab in Patients With Advanced Solid Tumors is a phase 2 interventional study registered as NCT07541001 by Intra-IMMUSG Pte Ltd, with 60 participants enrolled, started 2021-08-30 and due to reach its primary completion in 2026-06-01. Interventions recorded: PRL3-ZUMAB.
Shares Intra-IMMUSG, PTP4A3, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Intra-IMMUSG, PTP4A3, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.